olivLaw · US equity research
Trulieve Cannabis Corp. TRLV
Medicinal Chemicals & Botanical Products · SIC 2833 · Vertical: Medicinal Chemicals & Botanical Products (SIC 2833)
Trulieve is a vertically integrated cannabis company operating across several US states and presenting itself as the largest cannabis retailer in the United States. Revenue in fiscal 2025 was 1.18 billion USD, and in the first quarter of 2026 it reached 287 million USD. The company is relevant now because the reclassification of medical marijuana to Schedule III could open new operating opportunities.
At the close of 04 Nov 2026, Trulieve Cannabis Corp. (TRLV) stock was 11.60 USD (+0.52% on the day), with market capitalisation 2.2 bn USD, beta 0.52, 52-week range 4.76–13.00 USD. Latest reported quarter (Q2 2026): revenue of 271.0 m USD (−10.3% YoY), net income of -406.1 m USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 59.8
- strong (55–70)
- Bollinger (20, 2)
- 9.74 – 11.50
- above the upper band · %B 1.05 · band width 16.6%
- SMA 50 / 200
- 11.21 / 8.86
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.05 / -0.08
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +8.9% | −1.1% | +10.0 pp | — |
| 3 months | +37.4% | −0.5% | +37.9 pp | — |
| 6 months | +18.5% | +4.4% | +14.1 pp | — |
| Year to date | +33.5% | +12.3% | +21.2 pp | — |
| 1 year | +75.2% | +13.5% | +61.7 pp | −39.5% |
| 3 years | +142.9% | +76.4% | +66.5 pp | −45.3% |
| 5 years | −58.6% | +63.7% | −122.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 284.3 m | 301.1 m | 297.8 m | 302.1 m | 288.2 m | 293.1 m | 286.8 m | 271.0 m |
| Cost of revenue | 111.0 m | 114.1 m | 114.5 m | 119.2 m | 118.3 m | 118.0 m | 116.7 m | 108.7 m |
| Gross profit | 173.3 m | 187.0 m | 183.2 m | 182.9 m | 169.9 m | 175.2 m | 170.1 m | 162.3 m |
| SG&A | 148.6 m | 157.9 m | 118.8 m | 101.1 m | 99.0 m | 126.3 m | 104.9 m | 101.8 m |
| Operating income | 618.0 k | 1.3 m | 33.3 m | 52.6 m | 42.2 m | 15.3 m | 35.7 m | -370.5 m |
| Depreciation & amortisation | 28.3 m | 28.6 m | 29.3 m | 29.4 m | 29.5 m | 29.4 m | 29.7 m | 25.7 m |
| Interest expense | 17.5 m | 14.6 m | 16.3 m | 16.4 m | 16.1 m | 14.7 m | 13.3 m | 12.8 m |
| Pre-tax income | -12.8 m | -12.9 m | 20.3 m | 38.9 m | 29.3 m | 2.9 m | 25.2 m | -383.4 m |
| Income tax | 47.4 m | 47.6 m | 52.5 m | 54.7 m | 53.0 m | 47.9 m | 21.9 m | 22.0 m |
| Net income | -61.6 m | -62.5 m | -33.8 m | -16.1 m | -28.8 m | -43.6 m | 2.3 m | -406.1 m |
| Diluted EPS | -0.32 | -0.33 ≈ | -0.16 | -0.08 ≈ | -0.15 ≈ | -0.23 ≈ | — | — |
| Operating cash flow | 30.3 m ≈ | 30.7 m | 51.1 m | 86.1 m ≈ | 76.4 m ≈ | 59.2 m | 55.7 m | 53.1 m ≈ |
| Capex | 38.1 m ≈ | 42.7 m | 16.9 m | 11.6 m ≈ | 12.3 m ≈ | 3.4 m | 13.5 m | 21.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | ⚠ 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 252.8 m | 521.5 m | 931.9 m | 1.2 bn | 1.1 bn | 1.2 bn | 1.2 bn |
| Revenue YoY | unavailable | +106.3% | — | +30.7% | −7.3% | +5.1% | −0.4% |
| Net income | 53.1 m | 63.0 m | 17.4 m | -252.7 m | -533.1 m | -160.6 m | -122.2 m |
| Net income YoY | unavailable | +18.7% | — | −1,548.7% | unavailable | unavailable | unavailable |
| Diluted EPS | 0.46 | 0.53 | 0.21 | -0.95 | -2.28 | -0.79 | -0.58 |
| Diluted EPS YoY | unavailable | +15.2% | — | −552.4% | unavailable | unavailable | unavailable |
| net % | 21.0% | 12.1% | 1.9% | -20.7% | -47.2% | -13.5% | -10.3% |
| Free cash flow | -52.8 m | -298.0 k | -263.0 m | -141.7 m | 161.6 m | 148.9 m | 228.6 m |
The series breaks before 2021: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 255.5 m USD
- Financial debt
- 136.7 m USD
- Net debt
- -118.8 m USD
- Equity
- 1.1 bn USD
- Total assets
- 2.7 bn USD
- Debt / equity
- 0.12x
- Current ratio
- 4.43x
- ROE
- -10.2%
- ROA
- -4.4%
- FCF margin
- 19.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 521.5 m | 931.9 m | 1.2 bn | 1.1 bn | 1.2 bn | 1.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Cost of revenue | 135.1 m | 365.4 m | 529.1 m | 540.6 m | 470.7 m | 470.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Gross profit | 386.4 m | 566.6 m | 689.1 m | 588.6 m | 715.7 m | 711.2 m | SEC (XBRL)· 26 Feb 2026verified |
| SG&A | — | — | — | 386.2 m | 510.5 m | 445.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | 218.3 m | 204.1 m | 50.2 m | -221.6 m | 97.8 m | 143.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 12.6 m | 45.8 m | 116.4 m | 109.8 m | 112.8 m | 117.6 m | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | 230.9 m ≈ | 249.8 m ≈ | 166.5 m ≈ | -111.8 m ≈ | 210.6 m ≈ | 261.1 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Interest expense | 20.2 m | 29.1 m | 73.4 m | 81.6 m | 62.2 m | 63.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Pre-tax income | 157.4 m | 176.2 m | -19.2 m | -284.5 m | 42.7 m | 91.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | 94.5 m | 145.7 m | 163.4 m | 151.4 m | 197.6 m | 208.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Net income | 63.0 m | 17.4 m | -252.7 m | -533.1 m | -160.6 m | -122.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | 0.53 | 0.21 | -0.95 | -2.28 | -0.79 | -0.58 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 118.3 m | 146.8 m | 188.0 m | 189.0 m | 190.0 m | 191.3 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 146.7 m | 226.6 m | 207.2 m | 201.4 m | 238.8 m | 255.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Receivables | 308.0 k | 8.9 m | 6.5 m | 6.7 m | 8.3 m | 10.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Inventories | 98.3 m | 212.2 m | 276.5 m | 213.1 m | 231.4 m | 242.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 261.5 m | 524.4 m | 593.5 m | 477.3 m | 604.6 m | 562.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 314.0 m | 779.9 m | 743.3 m | 676.4 m | 716.1 m | 670.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Goodwill | 67.2 m | 765.4 m | 791.5 m | 483.9 m | 483.9 m | 483.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Intangibles (excl. goodwill) | 92.6 m | 1.1 bn | 984.8 m | 917.2 m | 859.5 m | 798.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 809.8 m | 3.4 bn | 3.4 bn | 2.7 bn | 2.9 bn | 2.7 bn | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 9.2 m | 14.8 m | 15.9 m | 28.2 m | 20.2 m | 26.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Long-term debt | — | 462.9 m | 541.7 m | 363.2 m | 364.8 m | 136.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 76.1 m | 168.9 m | 210.3 m | 114.8 m | 138.5 m | 126.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 361.9 m | 1.3 bn | 1.5 bn | 1.3 bn | 1.6 bn | 1.6 bn | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 447.9 m | 2.1 bn | 1.9 bn | 1.4 bn | 1.2 bn | 1.1 bn | SEC (XBRL)· 26 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 99.6 m | 12.9 m | 23.1 m | 201.8 m | 271.5 m | 272.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 99.9 m | 275.9 m | 164.7 m | 40.2 m | 122.6 m | 44.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | -298.0 k ≈ | -263.0 m ≈ | -141.7 m ≈ | 161.6 m ≈ | 148.9 m ≈ | 228.6 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -174.7 m | -215.2 m | -215.1 m | -37.5 m | -206.6 m | 13.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | 129.9 m | 289.2 m | 177.8 m | -175.6 m | -33.4 m | -270.5 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 2.2 bn USD
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 15.86 – 24.20 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)15.86 – 24.20 (Mid 19.07)WACC 9.0% · starting FCFF 242.0 m USD · terminal value share of EV 73%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): -21.5%
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -25.6% | 0 (vs peers) | 24% |
| Net margin · Quality | -41.8% | 13 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -1.0% | 0 (on a fixed band) | 19% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -4.9x | 0 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 5.9x | 100 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 8.7% | 100 (on a fixed band) | 19% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality5/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial100/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
TRULIEVE CANNABIS CORP. (TRLV). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 1.2 bn USD in 2025; YoY growth -0.4%; net margin -41.8%; ROE -48.2%.
The estimated value range is 15.86–24.20 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 19.07 USD, the price of 11.60 USD leaves a potential of 64.4% (value / price − 1) and a margin of safety of 39.2% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 5.9x
- FCF yield: 8.7%
- The price is below the estimated value range
What contradicts it
- ROIC: -25.6%
- Net margin: -41.8%
- Revenue CAGR 3Y: -1.0%
- Interest coverage: -4.9x
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Medicinal Chemicals & Botanical Products (SIC 2833) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TRLVTrulieve Cannabis Corp. | 2.2 bn | — | -48.2% | -41.8% | −0.4% | +75% / +143% |
| TLRYTilray Brands, Inc. | 437.5 m | — | -10.4% | -17.1% | +11.5% | −63% / −84% |
| USNAUsana Health Sciences, Inc. | 264.8 m | — | -4.2% | -2.4% | unavailable | −28% / −70% |
| NAGENiagen Bioscience, Inc. | 199.6 m | 21.3 | 13.3% | 8.4% | +29.9% | −63% / +81% |
| MDWDMediwound Ltd. | 182.3 m | — | -63.9% | -140.8% | −16.1% | −21% / +59% |
| FTLFFitlife Brands, Inc. | 76.8 m | 13.1 | 14.1% | 6.2% | +26.4% | −56% / −15% |
| BTMDbiote Corp. | 71.6 m | 11.8 | — | 3.2% | −2.5% | −55% / −75% |
| NAIINatural Alternatives International, Inc. | 24.3 m | — | -35.0% | -14.5% | +9.7% | −70% / −81% |
| MTEXMannatech Inc | 16.7 m | — | -1,490.1% | -6.9% | −8.3% | −8% / −3% |
| BONBon Natural Life Limited | 4.4 m | — | -3.9% | -10.7% | −21.7% | −39% / −99% |
| CRONCronos Group Inc. | — | — | 6.5% | 39.1% | +24.6% | +42% / +74% |
| CGCCanopy Growth Corp | — | — | -39.9% | -79.2% | +5.8% | −36% / −87% |
| ACBAurora Cannabis Inc | — | — | 0.3% | 0.5% | +27.3% | +14% / +14% |
| GLASGlass House Brands Inc. | — | — | -31.2% | -16.3% | −9.4% | −57% / −45% |
| SNDLSNDL Inc. | — | — | -1.4% | -1.7% | +2.8% | −20% / −1% |
| IMCCIM Cannabis Corp. | — | — | -1,496.2% | -20.7% | +1.3% | −99% / −99% |
1- and 3-year price returns: for TRLV from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Trulieve is a vertically integrated cannabis company operating across several US states and presenting itself as the largest cannabis retailer in the United States. Revenue in fiscal 2025 was 1.18 billion USD 1, and in the first quarter of 2026 it reached 287 million USD 3. The company is relevant now because the reclassification of medical marijuana to Schedule III could open new operating opportunities 2.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Federal illegalityhigh
Cannabis remains illegal in certain respects under federal law, which could lead to proceedings against the company 1.
- Limited banking accessmedium
Banks and card networks often refuse cannabis businesses, which could force cash-only operations 1.
- Tax uncertaintyhigh
The position on Section 280E and uncertain tax liabilities could generate additional costs 13.
- Competition and pricingmedium
Entry of better financed competitors could intensify pressure on prices and margins 1.
- Indebtednessmedium
Secured notes and other debt could limit financial flexibility if results decline 13.
Investment thesis
What would need to be true (bull case)
- If federal rescheduling translates into easier operations, the company could benefit from its strong retail position and vertical integration.
- First quarter 2026 results showed positive profit and operating cash flow, which could support investment.
- Entry into new markets such as Texas could add medium-term growth.
What would break the thesis
- If price pressure continues, retail revenue could remain under pressure.
- Tax uncertainty and debt could limit the capacity to invest.
- The reduction in the number of dispensaries shows that expansion could be more fragile than it appears.
What to watch
- Completion of DEA registrations for medical operations2026
- Quarterly results and gross margin trendQ3 2026
- Final Texas licensenext 10-K
- Developments in the Section 280E tax positionnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Trulieve produces, processes and sells medical and adult-use cannabis through its own network of dispensaries and through wholesale distribution channels 1. As of December 31, 2025 it operated 233 dispensaries and 15 cultivation and processing facilities in nine states 1. By June 30, 2026 the number of dispensaries had fallen to 206 and the company operated in four states, according to its latest quarterly report 2.
The company is organized into three regional hubs, Southeast, Northeast and Southwest, each anchored in key markets 1. In the first quarter of 2026 retail accounted for 92% of revenue and gross margin was 59% 3. The vertically integrated supply chain gives the company control over product quality and brand experience 1.
Segments
Market context
Medical cannabis is legal in all states where the company operates, and adult-use cannabis is legal in 24 states plus the District of Columbia 1. The market remains fragmented, with small and regional operators, but high entry barriers due to the limited number of licenses 1.
The rescheduling of medical marijuana to Schedule III and the broader expedited review of marijuana classification could change the registration and operating framework in coming years 23. The outcome depends on completing DEA approvals and later decisions by federal authorities 2.
Competitive position
Competition comes from local and regional operators, other multi-state operators entering the company's markets, as well as the illicit market and intoxicating hemp products 1. The company says larger and better financed competitors could materially affect its business 1.
- Other multi-state cannabis operators
Operators competing directly in several of the company's markets, according to the annual report.
- Regional and single-state operators
Companies localized in a single state or region, making up most of the direct competition.
- The illicit cannabis market
Indirect competition that affects sales through unlicensed products.
- Intoxicating hemp product makers and retailers
Indirect competition from substitute products.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report11 Aug 2026Material agreement · Item 3.02 · Item 3.03 · Amendments to articles or bylaws · Financial statements and exhibits
- Quarterly report07 Aug 2026
- Current report07 Aug 2026Acquisition or disposition of assets · Regulation FD disclosure · Financial statements and exhibits
- Current report05 Aug 2026Shareholder vote · Financial statements and exhibits
- Current report02 Jul 2026Departure or appointment of officers · Financial statements and exhibits
- Proxy statement25 Jun 2026
- Current report12 Jun 2026Departure or appointment of officers · Financial statements and exhibits
- Current report11 Jun 2026Shareholder vote · Financial statements and exhibits
- Current report09 Jun 2026Other events · Financial statements and exhibits
- Current report04 Jun 2026Material agreement · Acquisition or disposition of assets · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Trulieve Cannabis Corp. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Trulieve Cannabis Corp. · 07 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Trulieve Cannabis Corp. · 07 May 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.